1127 related articles for article (PubMed ID: 29575516)
1. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
5. Liver fibrosis quantified by image morphometry predicts clinical outcomes in patients with non-alcoholic fatty liver disease.
Wang Z; Jeffrey GP; Huang Y; De Boer B; Garas G; Wallace M; Bertot L; Adams LA
Hepatol Int; 2023 Oct; 17(5):1162-1169. PubMed ID: 37358741
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
[TBL] [Abstract][Full Text] [Related]
8. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
[TBL] [Abstract][Full Text] [Related]
10. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
[TBL] [Abstract][Full Text] [Related]
11. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
[TBL] [Abstract][Full Text] [Related]
13. Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models.
Chinnaratha MA; Jeffrey GP; MacQuillan G; Rossi E; de Boer BW; Speers DJ; Adams LA
Liver Int; 2014 May; 34(5):720-7. PubMed ID: 24034439
[TBL] [Abstract][Full Text] [Related]
14. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
[TBL] [Abstract][Full Text] [Related]
15. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
[TBL] [Abstract][Full Text] [Related]
16. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
18. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
20. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE; Lee JA; Vali Y; Alzoubi O; Staufer K; Trauner M; Paternostro R; Stauber RE; Holleboom AG; van Dijk AM; Mak AL; Boursier J; de Saint Loup M; Shima T; Bugianesi E; Gaia S; Armandi A; Shalimar ; Lupșor-Platon M; Wong VW; Li G; Wong GL; Cobbold J; Karlas T; Wiegand J; Sebastiani G; Tsochatzis E; Liguori A; Yoneda M; Nakajima A; Hagström H; Akbari C; Hirooka M; Chan WK; Mahadeva S; Rajaram R; Zheng MH; George J; Eslam M; Petta S; Pennisi G; Viganò M; Ridolfo S; Aithal GP; Palaniyappan N; Lee DH; Ekstedt M; Nasr P; Cassinotto C; de Lédinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Martic M; Tuthill T; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):704-713. PubMed ID: 37290471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
